Recce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
"Illustration representing the Phase I/II trial of RECCE 327 by Recce Pharmaceuticals"
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced it dosed the next cohort of healthy subjects at 3,000mg within a fast infusion rate of 20-minutes in a Phase I/II trial evaluating its lead candidate, RECCE® 327 (R327).
“We’re pleased to continue advancing the clinical profile of R327, which has demonstrated safe and efficacious potential against a broad range of antibiotic-resistant pathogens across multiple studies,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals. “We’ve observed efficacy when applied topically to patients with diabetic foot ulcer infections, and the additional infusion time at 3,000mg over 20 minutes in this study highlights a compelling safety profile with the potential to treat the millions of patients worldwide that suffer from UTIs or urosepsis each year.”
Recce is exploring multiple infusion times of 15, 20, 30, and 45 minutes, and 1 hour at 3,000mg, which is viewed as R327’s optimal dosing therapeutic window. The Company has established that the dose of 3,000mg, administered at varying infusion times between 15 and 60 minutes, has been proven safe in participants. The efficacy of R327 via intravenous administration will be made available at the completion of the Phase I/II trial in line with the study protocol.
More information on this trial can be found at the Australia New Zealand Clinical Trial Registry under the trial ID ACTRN12623000448640.
